ChiCTR2400090419 版本V1.0 版本创建时间2024/09/29 16:00:34 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400090419 

最近更新日期:

Date of Last Refreshed on:

2024-09-29 16:00:18 

注册时间:

Date of Registration:

2024-09-29 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

小剂量艾司氯胺酮对剖宫产产妇术后镇痛及抗抑郁效果的观察的回顾性研究

Public title:

A retrospective study of the Observations on the Effects of Low-Dose Esketamine for Postoperative Analgesia and Antidepressant Effects in Cesarean Section Patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

小剂量艾司氯胺酮对剖宫产产妇术后镇痛及抗抑郁效果的观察的回顾性研究

Scientific title:

A retrospective study of the Observations on the Effects of Low-Dose Esketamine for Postoperative Analgesia and Antidepressant Effects in Cesarean Section Patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘万超 

研究负责人:

刘万超 

Applicant:

Liu Wanchao 

Study leader:

Liu Wanchao 

申请注册联系人电话:

Applicant telephone:

+86 183 6120 5651

研究负责人电话:

Study leader's
telephone:

+86 183 6120 5651

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

975886026@qq.com

研究负责人电子邮件:

Study leader's E-mail:

975886026@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省江阴市寿山路163号

研究负责人通讯地址:

江苏省江阴市寿山路163号

Applicant address:

163 Shoushan Road, Jiangyin City, Jiangsu Province

Study leader's address:

163 Shoushan Road, Jiangyin City, Jiangsu Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

江阴市人民医院

Applicant's institution:

Jiangyin People's Hospital

研究负责人所在单位:

江阴市人民医院

Affiliation of the Leader:

Jiangyin People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

[2024]伦审研第(095)号(复)

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

江阴市人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of Jiangyin People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-06-13 00:00:00

伦理委员会联系人:

张婷

Contact Name of the ethic committee:

Zhang Ting

伦理委员会联系地址:

江苏省江阴市寿山路163号

Contact Address of the ethic committee:

163 Shoushan Road, Jiangyin City, Jiangsu Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 510 8687 9073

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

江阴市人民医院

Primary sponsor:

Jiangyin People's Hospital

研究实施负责(组长)单位地址:

江苏省江阴市寿山路163号

Primary sponsor's address:

163 Shoushan Road, Jiangyin City, Jiangsu Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏省

市(区县):

江阴市

Country:

China

Province:

Jiangsu

City:

Jiangyin

单位(医院):

江阴市人民医院

具体地址:

江苏省江阴市寿山路163号

Institution
hospital:

Jiangyin People's Hospital

Address:

163 Shoushan Road, Jiangyin City, Jiangsu Province

经费或物资来源:

自筹

Source(s) of funding:

Raise independently

研究疾病:

产后疼痛和抑郁  

Target disease:

Postpartum pain and depression

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

探讨小剂量艾司氯胺酮用于剖宫产产妇的镇痛效果、 安全性及对产后抑郁的影响  

Objectives of Study:

Exploring the Analgesic Effect, Safety, and Impact on Postpartum Depression of Low-Dose Esketamine in Cesarean Section Patients

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)年龄18--40岁; (2)ASA II级; (3)妊娠大于37周; (4)要求接受术后镇痛治疗; (5)无严重心脑血管疾病; (6)产妇能与随访者进行良好的沟通; (7)自愿参加本次研究并签署相关知情同意?。

Inclusion criteria

(1)Age 18-40 years; (2)ASA Class II; (3)Pregnancy over 37 weeks; (4)Requires postoperative analgesic treatment; (5)No severe cardiovascular or cerebrovascular diseases; (6)Able to communicate well with the follow-up personnel; (7)Voluntarily participates in the study and signs the informed consent.

排除标准:

(1)有妊娠高血压、甲状腺功能异常、先兆子痫和子痫、精神病、无法交流疼痛反应者; (2) 子宫活动异常增加者,例如强直性子宫收缩、胎盘早剥与脐带脱垂者; (3) 有脊柱外伤史或畸形等硬膜外置管禁忌症者; (4) 阿片类药物过敏或有该类药物滥用史者 (5) 有血压或颅内压升高严重风险的患者; (6) 控制不佳或未经治疗的高血压患者; (7) 胎儿严重异常; (8) 凶险型前置胎盘; (9) 已行分娩镇痛患者。

Exclusion criteria:

1) Persons with pregnancy-induced hypertension, thyroid dysfunction, preeclampsia and eclampsia, psychosis, inability to communicate pain response; (2) Abnormal increase in uterine activity, such as tetanic contractions, placental abruption, and umbilical cord prolapse; (3) Patients with contraindications for epidural catheterization such as spinal injury history or deformity; (4) People who are allergic to opioids or have a history of abuse of such drugs (5) Patients at serious risk of elevated blood pressure or intracranial pressure; (6) Patients with poorly controlled or untreated hypertension; (7) severe fetal abnormalities; (8) dangerous placenta previa; (9) Patients with labor analgesia.

研究实施时间:

Study execute time:

From 2024-10-01 00:00:00 To 2025-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-10-01 00:00:00 To 2024-12-31 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

60

Group:

Control Group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

艾司氯胺酮 I 组

样本量:

60

Group:

Esketamine Group I

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

艾司氯胺酮 II 组

样本量:

60

Group:

Esketamine Group II

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

江阴 

Country:

China

Province:

Jiangsu

City:

Jiangyin

单位(医院):

江阴市人民医院 

单位级别:

三甲 

Institution
hospital:

Jiangyin People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

EPDS评分

指标类型:

主要指标

Outcome:

EPDS scores

Type:

Primary indicator

测量时间点:

产后42天

测量方法:

Measure time point of outcome:

42 days postpartum

Measure method:

指标中文名:

疼痛评分

指标类型:

次要指标

Outcome:

VAS score

Type:

Secondary indicator

测量时间点:

产后48小时内

测量方法:

Measure time point of outcome:

Within 48 hours postpartum

Measure method:

指标中文名:

产前和产后7天、28天的炎性细胞因子(IL-6)、神经递质(5-HT)以及激素(PRL)水平

指标类型:

主要指标

Outcome:

nflammatory cytokine (IL-6), neurotransmitter (5-HT), and hormone (PRL) levels before and after 7 and 28 days postpartum

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

产妇住院天数及满意度

指标类型:

次要指标

Outcome:

Maternal hospitalization days and satisfaction

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 40 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No sharing of data

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用病例记录表进行数据收集和管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection and management were carried out with case record form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-09-29 16:00:18